Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder. Twenty-four-week placebo-controlled dose-ranging study

British Journal of Psychiatry

Volumn 178, Issue JULY, 2001, Pages 15-22

  Allgulander, C ^a   Hackett, D ^a   Salinas, E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VENLAFAXINE; UNCLASSIFIED DRUG; VENLAFAXINE ER;

ADULT; AGED; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTIGO; XEROSTOMIA; DRUG INDUCED DISEASE; DRUG RELEASE; DRUG RESPONSE; DRUG TOLERANCE; DRUG WITHDRAWAL; SEXUAL DYSFUNCTION; SUSTAINED RELEASE PREPARATION; SWEATING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CHRONIC DISEASE; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES;

EID: 0034931866     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.179.1.15     Document Type: Article

References (24)

1. Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein
2. Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man
3. Recovery rates in generalised anxiety disorder following psychological therapy: An analysis of clinically significant change in the STAI-T across outcome studies since 1990
4. Buspirone: A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic
5. The assessment of anxiety by rating
6. Comorbidity as a fundamental feature of generalised anxiety disorders: Results from the National Comorbidity Survey (NCS)
7. GAD-associated impairment controlling for MDE in the NCS and MIDUS surveys
8. Venlafaxine occupation at the noradrenaline reuptake site; in vivo determination in healthy volunteers
9. Comorbidity and boundaries of affective disorders with anxiety disorders and substance abuse: Results of an international task force
10. Superiority of clomipramine over imipramine in the treatment of panic disorder: A placebo-controlled trial
11. Effects of abrupt discontinuation
12. Antidepressants for the treatment of generalised anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam
13. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial
14. Lorazepam - Efficacy, side-effects, and rebound phenomena
15. Resistance to the anti-anxiety effect of buspirone in patients with a history of benzodiazepine use
16. The brief scale for anxiety: A subdivision of the comprehensive psychopathological rating scale
17. The benzodiazepine withdrawal symptom questionnaire
18. Assessment of social adjustment by patient self-report
19. DSM-III-R generalised anxiety disorder in the National Comorbidity Survey
20. The hospital anxiety and depression scale
21. Anxiety disorders: A review of tricyclic antidepressants and selective serotonin reuptake inhibitors